Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9822181
APP PUB NO 20160200827A1
SERIAL NO

14913632

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to sequence-optimized CD 123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MACROGENICS INC9640 MEDICAL CENTER DRIVE ROCKVILLE MD 20850

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Alderson, Ralph Froman North Potomac, US 8 69
Bonvini, Ezio Potomac, US 73 948
Chichili, Gurunadh Reddy Germantown, US 12 90
Huang, Ling Bethesda, US 138 3413
Johnson, Leslie S Damestown, US 170 4245
Moore, Paul A Bethesda, US 236 2276

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 21, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 21, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00